Ketamine-Induced Uropathy in Children

What Is Ketamine-Induced Uropathy?

Ketamine-induced uropathy can involve inflammation, ulceration and progressive scarring of the bladder. Commonly reported symptoms include pelvic or bladder pain, urinary urgency, passing urine frequently, waking at night to urinate and blood in the urine. Severe disease may reduce bladder capacity and, in some cases, affect the ureters or kidneys.

The condition was described as a distinct clinical problem in a 2007 Urology case series. Its biological mechanisms remain under investigation, but ketamine and its metabolites are thought to injure the urinary lining and promote inflammation and fibrosis. Risk appears related to repeated exposure, although no amount or frequency can reliably predict who will develop damage.

Why Does a Pediatric Ketamine Uropathy Clinic Matter?

The early report from the United Kingdom’s first clinic for patients under 16 offers an initial look at the children and young people reaching specialist care. Because it describes a selected clinical population, it should not be used to estimate how common ketamine-related bladder disease is among all adolescents.

Its importance lies in showing that clinically significant urinary harm can occur before adulthood. Children may delay disclosure because of stigma, fear or uncertainty about confidentiality. Urinary symptoms can also be mistaken for recurrent infection, making sensitive questions about ketamine exposure and appropriate urine, kidney and bladder assessment important when symptoms persist.

Can Ketamine-Related Bladder Damage Be Treated?

Early recognition and complete cessation of ketamine offer the best opportunity for symptoms to improve and may help prevent further injury. Care may include pain management, bladder-directed treatment and monitoring of kidney function, but antibiotics are not appropriate unless testing supports a bacterial infection.

Advanced disease can require specialist procedures or reconstructive surgery, and symptoms may persist even after ketamine is stopped. Young patients therefore need integrated support rather than bladder treatment alone, including confidential substance-use care, mental health assessment and safeguarding appropriate to their age and circumstances.